ClinicalTrials.gg
Drug

Emicizumab clinical trials

Also written Hemlibra, RO5534262 and ACE910.

studies test it
26
open now
7
in phase 3
14
first study started
2015

How each study uses emicizumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the emicizumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
16 Nov 2017 · HEMLIBRA · BLA 761083 (FDA, Drugs@FDA)
European Union
23 Feb 2018 · Hemlibra · EMEA/H/C/004406 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Emicizumab
21
Hemlibra (R)
2
Emicizumab Injection
2

Brand

Hemlibra
17

Development codes

RO5534262
11
ACE910
10
RG6013
8

Studies by the year they started

26 studies that test it; most in 2021 (6)

Studies that test emicizumab, by start year
YearStudies
20151
20162
20172
20183
20191
20201
20216
20224
20231
20241
20252
20262

By phase

A phase 1/2 study counts in both.

Phase 1
2
Phase 2
4
Phase 3
14
Phase 4
7
No phase
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 13 · Other 13

Hoffmann-La Roche (11) · Indiana Hemophilia &Thrombosis Center, Inc. (2) · Margaret Ragni (2) · University of Washington (1) · GWT-TUD GmbH (1) · Cliniques universitaires Saint-Luc- Université Catholique de Louvain (1) · Versiti Blood Health (1) · Dhaka Medical College (1)

Often tested with

Tested in the same studies.

Preventive Intervention (1) · Fitusiran (1) · Anti-inhibitor coagulant complex (1) · Factor VIII-Fc fusion protein (1) · BAX 855 (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 1 phase 3 study under way

Emicizumab is the comparator. A study of two new drugs counts under both.

  • 1NXT007 · Hoffmann-La Roche · next primary completion Feb 2028
Reaching primary completion within a year · 3, 1 in phase 3

Studies that test emicizumab, phase 3 first.

Studies

Open first, then newest update. How each study uses emicizumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 26

See all 26 studies that test emicizumab →

Given beside what is tested · 2 — emicizumab is usual care or a partner of the new treatment
As the comparator · 1 — what is tested is compared with emicizumab

What changed recently

From the registry's own updates since Oct 18, 2026.

Codes

What other systems call emicizumab · ClinicalTrials.gg INT000473

  • MeSH (NLM) C000608208emicizumabConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 7NL2E3F6K3EMICIZUMABConfirmed FDA, NLM, Wikidata
  • RxNorm 1989794Confirmed FDA, Wikidata
  • Wikidata Q27155409emicizumabConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C159541EmicizumabOne source FDA
  • DrugBank DB13923One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.